A detailed history of Kestra Advisory Services, LLC transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Kestra Advisory Services, LLC holds 29,774 shares of AKBA stock, worth $50,615. This represents 0.0% of its overall portfolio holdings.

Number of Shares
29,774
Previous 16,474 80.73%
Holding current value
$50,615
Previous $59,000 35.59%
% of portfolio
0.0%
Previous 0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 13, 2025

BUY
$2.7 - $4.01 $35,910 - $53,333
13,300 Added 80.73%
29,774 $80,000
Q2 2025

Aug 14, 2025

BUY
$1.55 - $3.97 $25,534 - $65,401
16,474 New
16,474 $59,000

Others Institutions Holding AKBA

About Akebia Therapeutics, Inc.


  • Ticker AKBA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 183,848,992
  • Market Cap $313M
  • Description
  • Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...
More about AKBA
Track This Portfolio

Track Kestra Advisory Services, LLC Portfolio

Follow Kestra Advisory Services, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Kestra Advisory Services, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Kestra Advisory Services, LLC with notifications on news.